{"url_path":"/sec/tyra/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-220638-index.html","accession_number":"0001193125-26-220638","cik":"0001863127","ticker":"TYRA","issuer_name":"Tyra Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-220638-index.html","primary_entity_key":"0001863127","primary_entity_name":"Tyra Biosciences, Inc."},"word_count":142,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\nIn accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing."}